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Oncolytic viruses and radiotherapy represent two diverse areas of cancer therapy, utiliz-
ing quite different treatment modalities and with non-overlapping cytotoxicity profiles. It 
is, therefore, an intriguing possibility to consider that oncolytic (“cancer-killing”) viruses 
may act as cancer-selective radiosensitizers, enhancing the therapeutic consequences 
of radiation treatment on tumors while exerting minimal effects on normal tissue. There is 
a solid mechanistic basis for this potential synergy, with many viruses having developed 
strategies to inhibit cellular DNA repair pathways in order to protect themselves, during 
genome replication, from unwanted interference by cell processes that are normally 
triggered by DNA damage. Exploiting these abilities to inhibit cellular DNA repair follow-
ing damage by therapeutic irradiation may well augment the anticancer potency of the 
approach. In this review, we focus on oncolytic adenovirus, the most widely developed 
and best understood oncolytic virus, and explore its various mechanisms for modulating 
cellular DNA repair pathways. The most obvious effects of the various adenovirus sero-
types are to interfere with activity of the MRE11-Rad50-Nbs1 complex, temporally one 
of the first sensors of double-stranded DNA damage, and inhibition of DNA ligase IV, a 
central repair enzyme for healing double-stranded breaks by non-homologous end join-
ing (NHEJ). There have been several preclinical and clinical studies of this approach and 
we assess the current state of progress. In addition, oncolytic viruses provide the option 
to promote a localized proinflammatory response, both by mediating immunogenic 
death of cancer cells by oncosis and also by encoding and expressing proinflammatory 
biologics within the tumor microenvironment. Both of these approaches provide exciting 
potential to augment the known immunological consequences of radiotherapy, aiming to 
develop systems capable of creating a systemic anticancer immune response following 
localized tumor treatment.
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iNTRODUCTiON
Radiation therapy is responsible for an estimated 40% of all the cured cancers worldwide (1). Modern 
radiotherapy techniques allow for reduced toxicity due to improved accuracy and modulation of 
radiation delivery. The therapeutic window between efficacy and toxicity is often optimized by the 
FigURe 1 | Ionizing radiation causes fatal double-strand breaks. DNA damage repair is mediated by two main pathways: homologous recombination repair (HRR) 
and non-homologous end joining (NHEJ). (A) In HRR, damage is sensed by the MRE11–Rad50–Nbs1 (MRN) complex, consisting of MRE11, Rad50, and Nbs1, 
which facilitates recruitment of downstream mediators to the site of damage. These include replication protein A (RPA), the Rad family of proteins and BRCA1 and 
BRCA2. Final sequence homology for the damaged DNA is provided by invading, and requires the presence of, the sister chromatid. (B) NHEJ is initiated by the 
recruitment of phosphatidylinositol-3-kinase-related kinase (PIKK) family such as ataxia-telangiectasia mutated (ATM). These facilitate the recognition of damaged 
strands by Ku70/Ku80, subsequent processing by DNA-PKcs and final repair and processing of strand ends by XRCC4 and DNA Ligase IV. The final product of 
both pathways is a repaired, complete strand of DNA.
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addition of a radiosensitizer. However, the development of novel 
radiosensitizers is challenging, with cytotoxic chemotherapy 
remaining the mainstay of radiosensitization in most solid organ 
tumors. There is an unmet need for rational development of 
radiation–drug combinations, as a relatively modest change in 
therapeutic index could have significant implications regarding 
improving outcomes. Apart from the addition of cetuximab to 
radical head and neck radiotherapy (2), no other targeted agent 
has been approved for radiosensitization in the last decade. 
Better understanding of the biological effects of radiation at a 
molecular level and the expanding availability of drugs that act 
on the specific pathways of radiobiological damage offers new 
opportunities. The unique nature of radiation injury and its 
cellular damage means that it is ideally suited for combination 
with oncolytic viruses. Here, we will discuss the nature of both 
radiation-induced DNA damage and the interaction between 
oncolytic adenoviral proteins and the DNA damage response, 
the behavior of oncolytic viruses in a cancer context and the 
proposed mechanism of synergy gained from their combination. 
We will also summarize the preclinical and clinical data to date, 
including toxicity therein, the role of the immune system in 
optimizing the effectiveness of combination therapy and, finally, 
the ability to arm oncolytic viruses to maximally contribute to 
effective synergy.
RADiATiON-iNDUCeD DNA DAMAge AND 
RePAiR
The therapeutic effect of radiation on cell kill is mediated 
through DNA damage, specifically double-strand DNA damage, 
resulting in irretrievable cell death. Here following is a basic 
overview of the two main types of DNA damage produced by 
ionizing radiation (see Figure 1). It is important to understand 
the role of both non-homologous end joining (NHEJ) and 
homologous recombination repair (HRR) in order to understand 
how the combination with oncolytic virus may prove useful in 
the future. NHEJ is classically described as occurring in the G1 
phase of cell division when there is no sister chromatid to act as a 
template. HRR is described mainly in G2/S phase when the pres-
ence of an undamaged chromatid acts as a template for repair 
of the affected DNA strand. Although the processes are not 
mutually exclusive, a cursory separation allows for an informed 
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mechanistic explanation. The role of the MRE11–Rad50–Nbs1 
(MRN) complex appears to be central to both forms of repair as 
a sensor for double-strand breaks (3).
Non-Homologous end Joining
Protein kinases belonging to the phosphatidylinositol-3-kinase-
related kinase (PIKK) family, such as ataxia-telangiectasia 
mutated (ATM) and ATR, are recruited to the site of DNA dam-
age. Recognition of the damaged strands is facilitated by Ku70/
Ku80. Subsequent recruitment of DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs), which autophosphorylates to allow 
release from the DNA, means that end processing and ligation of 
the strands can commence. This is primarily mediated by DNA 
ligase IV and X-ray repair cross-complementing group (XRCC4). 
Consequently, these often form the basis for translational work, 
with their presence indicating significant DNA damage in need 
of repair.
Homologous Recombination Repair
In contrast to NHEJ, HRR is a high fidelity repair mechanism 
for mammalian DNA. The double-strand break is sensed by the 
MRN complex, which processes the DNA into 3′ DNA single 
strands. The MRN complex allows for recruitment and activa-
tion of ATM, a key regulator of HRR. Autophosphorylation of 
ATM allows for downstream recruitment of repair proteins, such 
as BRCA1 and BRCA2, replication protein A (RPA), and other 
mediators such as the Rad family of proteins (4). Rad51 is a key 
protein as it mediates the invasion of the sister chromatid of the 
homologous strand to allow for accurate replication of DNA. The 
3′ end of the ssDNA invades the homologous strand of the sister 
chromatid to form a “displacement” loop and the sequence is then 
extended by synthesizing new DNA to form a Holliday junction. 
Gap filling occurs by DNA synthesis beyond the original break 
site before Rad54 facilitates release of the newly synthesized end 
(5). The DNA strand is then annealed with the other end of the 
ssDNA to complete the repair process.
Although these two pathways are key mediators of the DNA 
damage response pathway, it has become clear recently that post 
translational modifications have a key role to play in coordinating 
the cell’s repair (6). This can include modification of the proteins 
themselves, phosphorylation of cyclin dependent kinases to 
control cell phase, ubiquitylation and sumoylation, and the 
regulation of checkpoints.
ONCOLYTiC ADeNOviRUSeS AND THe 
DNA DAMAge ReSPONSe
The Concept of virotherapy
Oncolytic virotherapy uses lytic viruses that replicate selectively 
within cancer cells. This approach combines targeted cytotoxic-
ity with amplification of the therapeutic agent actually within 
tumor cells. With the first Federal Drugs Administration (FDA) 
approval of an oncolytic virus, Talimogene laherparepvec (T-vec) 
in 2015 (7), interest in oncolytic virotherapy is rapidly expanding. 
This is, however, a field that has been developing for many years 
(8) and a wealth of information is now available on the ways in 
which these viruses can be incorporated in the current anticancer 
therapeutic paradigms (9).
A range of oncolytic viruses are currently undergoing clinical 
trials, including adenovirus, vaccinia virus, herpes simplex virus 
(HSV), reovirus, poxvirus, coxsackievirus, Newcastle disease 
virus, measles virus, parvovirus, Seneca Valley Virus, poliovirus, 
and vesicular stomatitis virus (10). The mechanism through 
which these viruses lead to tumor cell death varies between types, 
however it is the ability of certain oncolytic viruses to interact 
with and inhibit the DNA damage response which is of particular 
interest with regard to combining treatment with radiotherapy 
(11). Nuclear-living DNA viruses might be particularly sensitive 
to cellular DNA repair mechanisms and, therefore, could have 
developed strategies to interact with these cellular factors to 
protect viral DNA from unwanted repair (12).
There is considerable evidence available on the ability of 
adenoviruses, in particular, to inhibit the DNA damage response 
as part of the normal virus life cycle (see Figure 2). It is hypoth-
esized that this is to prevent the linear double-stranded DNA 
viral genome from being recognized by the cell as a double-
stranded DNA break, potentially leading to concatemerization 
of virus genomes (13, 14). This was first observed using a range 
of mutant adenovirus type 5 and type 2 on KB cells, a human 
epidermoid cell line. The mutations were all located in the early 
region 4 (E4) region of the genome and, when both E4orf3 and 
E4orf6 regions were mutated, concatemerization of the viral 
genome was noted (15).
The effect of virus Proteins on the MRN 
Complex
The key cellular factor involved in sensing double-stranded DNA 
damage, particularly in the HRR pathway, is the MRN complex. 
The majority of the evidence relating to the interaction between 
adenoviral proteins and the DNA damage response is consistent 
with an effect on this complex. This was initially demonstrated 
by Stracker et al  (16). Adenoviral genome concatemers formed 
in cells infected with adenovirus serotype 5 (Ad5) lacking the E4 
region, but not with wild-type virus. However, no concatemers 
formed following infection with this mutant virus in cell lines 
containing any of mutant DNA ligase IV, DNA-PKcs, Nbs1, or 
MRE11, suggesting that these cellular proteins are all required 
for recognition and concatemerization of the adenoviral genome. 
In addition, in cells infected with the E4 mutant virus, the MRN 
complex could be seen to form foci surrounding viral replication 
centers. This paper was the first to provide evidence for MRN 
degradation mediated by the Ad5 E4orf6–E1b55K complex and 
MRN mislocalization mediated by Ad5 E4orf3 (16). These two 
mechanisms of MRN inhibition will be briefly explored below.
Degradation of the MRN Complex
Stracker et  al. initially demonstrated that intracellular levels of 
MRE11, Rad50, and Nbs1 decreased following infection with 
wild-type adenovirus serotype 5 (Ad5). This was due to enhanced 
protein turnover and was not seen following infection with 
E4-deficient Ad5. Infection with Ad5 mutants lacking different 
E4 genes demonstrated that there was no degradation of MRE11 
FigURe 2 | Adenovirus proteins interact with the DNA damage response. Double-strand breaks result in MRE11–Rad50–Nbs1 (MRN) complex activation of 
ataxia-telangiectasia mutated (ATM). This leads to phosphorylation of checkpoint kinase 2 (Chk2), activation of p53 and DNA damage repair through either 
non-homologous end joining (NHEJ) or homologous recombination repair (HRR). Single-stranded DNA is bound by replication protein A (RPA), which recruits ATM 
and RAD3-related (ATR) kinase, ATR-interacting protein (ATRIP), RAD9-RAD1-HUS1 and topoisomerase-IIβ-binding protein 1 (TOPBP1) to site. ATR phosphorylates 
checkpoint kinase 1 (Chk1) resulting in phosphorylation of the cell division cycle 25 (cdc25) phosphatases and a number of cellular changes, including DNA repair, 
effects on cell cycle, and stabilization of replication forks. Adenoviral proteins interact with a number of these steps, the most studied is adenovirus 5. Serotype of 
interacting adenovirus (Ad) denoted in black, adenovirus 5 protein identified as mediating interaction denoted in red.
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and Rad50 when cells were infected with Ad5 specifically lacking 
E4orf6–E1b55K. Furthermore, transfection of 293 cells with an 
E4orf6 expression vector resulted in MRE11 and Rad50 degrada-
tion, but not transfection with an expression vector containing 
mutant E4orf6 unable to form a complex with E1b55K. These, 
therefore, demonstrated that MRN degradation following infec-
tion with Ad5 is mediated by the E4orf6–E1b55K complex (16). 
Karen et al. further showed that this MRN degradation occurs 
prior to viral DNA accumulation (14).
The majority of evidence available is on the function of Ad5 
proteins. Stracker et  al. compared effects on MRN following 
infection with Ad5, Ad4, and Ad12. Infection of HeLa cells with 
all three serotypes led to decreased levels of MRE11 and Rad50. 
Likewise, transfection of 293 cells, which stably express Ad5 
E1b55K, with plasmids encoding E4orf6 from these serotypes 
led to degradation of all MRN components as well as p53. These 
results suggest that the ability of the E1b55K–E4orf6 complex to 
cause MRN degradation is conserved between these serotypes 
(17). Forrester et al. have also demonstrated MRE11 degradation 
following infection with Ad4, Ad5, and Ad12, but not follow-
ing infection with Ad3, Ad7, Ad9, and Ad11 (18). Therefore, 
although MRN degradation does appear to be targeted by a range 
of adenovirus serotypes, this is not conserved across all serotypes.
Relocalization of the MRN Complex
Stracker et  al. demonstrated that early after infection by 
adenovirus serotype 5 there appears to be relocalization of the 
MRN complex to areas of nuclear speckles partially overlapping 
with promyelocytic leukemia protein (PML) (16). In uninfected 
cells PML is found in oncogenic domains (PODs/ND10), 
however Ad5 E4orf3 causes relocalization of PML into nuclear 
tracks (16, 19, 20). This function appears to be conserved across 
serotypes and has been demonstrated for Ad2, Ad4, and Ad12 
E4orf3 (17, 20).
Stracker et  al. further showed that this MRN relocalization 
does not occur following infection with Ad5 lacking E4orf1 to 
E4orf3. Transfection of 293 cells with different expression vectors 
showed that expression of E4orf3 is sufficient for relocalization 
of the MRN complex to occur. The relocalization of MRN can, 
therefore, be linked directly to expression of Ad5 E4orf3 (16).
It has since been demonstrated that at later time points of 
infection Ad5 E4orf3 causes redistribution of the MRN complex 
to large single juxtanuclear cytoplasmic accumulations suggestive 
of aggresomes. These contain both E4orf3 and E1b55K, but seem 
to be able to form in the absence of the latter (21, 22). Aggresomes 
are areas of ubiquitin-rich cytoplasmic inclusions containing 
aggregated misfolded proteins and surrounded by a cage of the 
intermediate filament protein vimentin. They are proposed to be 
a cellular response to undegraded, aggregated protein (23) and 
their formation has been linked to a number of degenerative dis-
eases (24). Infection of A549 cells with an E4orf6/E4orf3 mutant 
Ad5 has been shown to greatly delay both aggresome formation 
and MRE11 localization to these areas, but not infection with 
Ad5 lacking only one of these viral proteins. Therefore, both Ad5 
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E4orf3 and E4orf6 can be seen to be key proteins involved in 
MRE11 relocalization during adenovirus infection, and appear 
to be functionally redundant (22). This relocalization to the cyto-
plasm accelerates degradation, thereby acting to protect the viral 
genome from recognition by the MRN complex and subsequent 
concatemerization (22).
Evidence provided by Liu et  al. suggests that E1b55K also 
plays an important role in the formation of MRN-containing 
cytoplasmic aggresomes. They utilized leptomycin B to inhibit 
an exportin interacting with an E1b55K nuclear export signal. In 
cells infected with an Ad5 E4orf6 deletion mutant, which allows 
visualization of MRN without its degradation, leptomycin B 
caused inhibition of MRE11 relocalization from the nucleus to 
juxtanuclear aggresomes. Furthermore, addition of leptomycin 
B to wild-type Ad5-infected cells resulted in a decreased rate 
of MRE11 depletion. Finally, there was minimal exportation of 
MRE11 out of the nucleus following infection of cells with either 
an E1b55K deletion mutant Ad5 or Ad5 containing mutant 
E1b55K unable to bind MRN. These results suggest that E1b55K 
plays an important role in the relocalization and degradation of 
the MRN complex following infection with Ad5 (22).
Interestingly, when comparing the effects of Ad5 E4orf3 with 
that of Ad4 and Ad12, Stracker et al. found that, though Nbs1 
appeared to be relocated away from viral replication centers fol-
lowing infection with Ad5, Ad4 and Ad12 did not have the same 
effect. These results would suggest that there are some differing 
effects on the relocalization of MRN components by different 
viral serotypes (17). Results published by Forrester et al., on the 
other hand, demonstrated that Ad5, Ad9, and Ad4 infection 
caused MRE11 relocalization to PML tracks. Infection with Ad3, 
Ad7, Ad11, and Ad12 resulted in relocalization of MRE11 to viral 
replication centers, as demonstrated by areas of RPA32 staining 
(18). These results are consistent with the view that different 
virus serotypes have varying effects on the MRN complex, and 
demonstrate some interesting differences in the results pertaining 
to Ad4 effects on members of the MRN complex.
The effects of virus Proteins on 
Phosphatidylinositol-3-Kinase-Related 
Kinase (PiKK) Family
Ataxia-telangiectasia mutated and ATR play pivotal roles in the 
cellular response to DNA damage. Brestovitsky et al. have recently 
presented some data on the role of Ad5 E4orf4 in inhibiting the 
DNA damage response through effects on these proteins and their 
substrates. Comparison of the phosphorylation status between 
cells infected with an Ad5 E4 deletion mutant and an Ad5 E4 
deletion mutant expressing only E4orf4 was carried out. Addition 
of E4orf4 significantly decreased the levels of phosphorylation 
of all ATM and ATR pathway proteins tested. This was shown 
to be dependent on E4orf4 interaction with the cellular protein 
phosphatase 2A (PP2A), which is known to dephosphorylate a 
number of proteins involved in the DDR including ATR, ATM, 
DNA-PK, and a range of their substrates. Both the cytopathic 
effect of E4orf4 and viral replication were significantly enhanced 
in cells lacking wild-type ATM and treated with an ATR inhibitor. 
Lack of wild-type ATM appeared to be beneficial during the early 
part of the virus life cycle and ATR inhibition during the late part 
of the virus life cycle. Moreover, expression of E4orf4 alone in 
cells was sufficient to inhibit DNA damage repair and to sensitize 
cells to the effects of genotoxic drugs even out with the context of 
infection (25). These results suggest inhibition of ATM and ATR 
is beneficial for the Ad5 viral life cycle and is mediated via an 
interaction between E4orf4 and PP2A.
The Effects of Virus Proteins on ATM
It has been suggested that, in the context of infection with Ad5 
mutant viruses lacking E4 and unable to interfere with the MRN 
complex, ATM plays an important role in viral inhibition (26). 
Given this and the results presented by Brestovitsky et al. (25), it 
is perhaps somewhat surprising that Forrester et al. demonstrated 
that infection of HeLa cells with Ad3, Ad4, Ad5, Ad7, Ad9, Ad11, 
and Ad12 all resulted in an increase in KAP1 phosphorylation, 
a marker of ATM activation. These results suggest that all viral 
serotypes investigated caused activation of ATM, however the 
kinetics of this varied between different serotypes (18).
This discrepancy can be explained by allowing for two differ-
ent mechanisms of ATM activation secondary to Ad5 infection. 
The first is proposed to be localized MRN-mediated ATM activa-
tion associated with blocking of viral genome replication at the 
earliest stages of the viral life cycle, prior to MRN inhibition by 
viral proteins. The second is an MRN-independent, global ATM 
activation that occurs subsequent to viral genome replication and 
does not impact on viral replication (27). Thus, the increase in 
KAP1 phosphorylation representative of increased ATM activity 
would not be necessarily associated with a direct impact on viral 
replication.
The Effects of Virus Proteins on ATR
ATR is traditionally associated with recognition of single-
stranded DNA (28). It would initially seem counter-intuitive for 
DNA viruses to have developed mechanisms of ATR interaction, 
nonetheless there is evidence that this is the case with adenovirus 
(25, 29, 30). It is frequently seen that infection with Ad5 leads 
to widespread histone 2AX phosphorylation (γH2AX) (31, 32). 
γH2AX is usually a marker for double-strand DNA breaks; how-
ever following infection, it can be seen throughout the nucleus. 
Nichols et  al. demonstrated that, in adenovirus-infected cells, 
the greatest decrease in phosphorylation of γH2AX following 
inhibition of ATM, ATR, or DNA-PK was seen following ATR 
inhibition, suggesting that ATR is the primary mediator of 
adenovirus-induced H2AX phosphorylation. Large amounts 
of γH2AX phosphorylation were seen after the onset of viral 
genome replication and some γH2AX of a differing pattern was 
seen following input of viral DNA at high multiplicities (31). This 
suggests that there is a cell response to the presence of viral DNA 
and potentially a mechanism by which there is ATR stimulation 
in response to viral replication. As ATR is known to respond to a 
wide range of cellular stresses (33), it may be that viral replication 
is a sufficient cell stressor to cause this. Alternatively, it has been 
demonstrated that a significant number of single-stranded DNA 
sequences are generated during viral replication (34), the virus 
may, therefore, have developed a mechanism to interact with ATR 
to prevent this stage of the viral replication cycle from causing 
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cell cycle arrest. There are a number of interactions between 
adenoviral proteins and the cellular ATR pathway that have been 
demonstrated.
E1b-AP5 (Ad E1b55K-associated protein 5) is a cellular protein 
that binds E1b55K in both Ad5-infected and Ad5-transformed 
cells (35). Blackford et al. have demonstrated that, in non-infected 
cells, this protein is localized to the nucleus but excluded from 
nucleoli. In the context of infection with adenovirus serotype 5 
and 12, however, E1b-AP5 levels increase and it is redistributed 
to viral replication centers where is colocalizes with RPA32. 
Moreover, infection with these virus serotypes also seemed to 
lead to relocalization of ATR-interacting protein (ATRIP) to viral 
replication centers and colocalization with RPA. The two different 
viral serotypes appeared to have different effects on ATR kinase 
substrates. Whereas Ad12 infection was associated with marked 
E1b-AP5 and ATR-dependent hyperphosphorylation of RPA32 
as well as hyperphosphorylation of Rad9, Ad5 infection did not 
have this effect, adding evidence that different virus serotypes have 
varying effects on the cell’s DNA damage response pathway (36). 
Forrester et al. have provided further evidence in support of this. 
The effect on checkpoint kinase 1 (Chk1) phosphorylation, an 
ATR substrate, in response to infection with different virus sero-
types was investigated. The authors demonstrated that the overall 
effect on phosphorylation levels, as well as the timeline over which 
changes took place, differed markedly between serotypes (18). In 
addition, the ATR-activator protein topoisomerase-IIβ-binding 
protein 1 (TOPBP1) was degraded following infection with Ad12, 
but not with other viral serotypes investigated (18, 30).
Carson et  al. provide evidence that the inhibition of ATR 
function by Ad5 is through effects on MRN. Cell lines with 
hypomorphic mutations in either Nbs1 or MRE11 were infected 
with either wild-type or E4-deleted Ad5. Results were compared 
when these cell lines were transduced with Nbs1 or MRE11 
wild-type cDNA. There was decreased phosphorylation of the 
ATR substrates Chk1 and RPA32, suggesting decreased ATR 
function, when cells infected with E4-deleted Ad5 did not express 
wild-type Nbs1 or MRE11. Furthermore, infection of HeLa cells 
with an E4-deleted Ad5 mutant virus lead to phosphorylation of 
Chk1 and RPA32. This was markedly decreased in cells infected 
with Ad5 expressing E4orf3, but not in cells infected with Ad5 
expressing E4orf6 or E1b55K. The authors did not find this effect 
on ATM signaling. Interestingly, when HeLa cells were infected 
with Ad5 mutants lacking E4, transfection with an Ad5 E4orf3 
expression vector was sufficient to lead to a decrease in phos-
phorylation of Chk1 and RPA32. This was not, however, the case 
following transfection with an Ad12 E4orf3 expression vector 
or with an Ad5 E4orf3 expression vector mutated to abrogate 
the protein’s ability to mislocalize MRN. Ultimately, the authors 
provided evidence that MRN is key in the hyperphosphorylation 
of ATR substrates following infection with Ad5 lacking E4, and 
that this can be abrogated through expression of Ad5 E4orf3 and 
subsequent mislocalization of the MRN complex (29).
The effects of virus Proteins on p53
The full range of p53’s effects within the cell is still being eluci-
dated; however, it is clear that p53 has an inherent role in the cell’s 
response to stressors and DNA damage (37, 38). It is, therefore, 
perhaps no surprise that its function is targeted by adenoviruses, 
though the exact effects of this targeting appear to vary between 
serotypes. Ad5 E4orf3 and E4orf6 are known to have an effect on 
p53 through interaction with the E1b55K protein (39, 40). Liu 
et al. have demonstrated that Ad5 E1b55K co-localizes with p53 
to aggresomes. Following transfection of 293 cells with E4orf6, 
the majority of cells demonstrated p53 depletion, and in those 
cells where p53 was visible, it was associated with E4orf6 in 
aggresomes (22). Harada et al. used a proteomics-based approach 
to demonstrate that the E1b55K–E4orf6 complex interacts with 
a number of cellular proteins to lead to the polyubiquitination 
of p53 in vitro (41). It is thought that E1b55K–E4orf6, therefore, 
leads to p53 depletion through ubiquitin-dependent proteasome-
mediated destruction.
The degradation of p53 does not appear to be conserved across 
all virus serotypes tested. Forrester et  al. have demonstrated 
that, though infection with Ad4, Ad5, and Ad12 leads to p53 
degradation, this does not occur following infection with Ad3, 
Ad7, Ad9, and Ad11. Interestingly, there appeared to be, in fact, 
a marked increase in p53 levels in cells infected with Ad3, Ad7, 
and Ad11. The authors present evidence that this is, however, not 
transcriptionally active. It was shown that MDM2 levels were 
decreased following infection with all virus serotypes investi-
gated, including those associated with increasing levels of p53. 
Furthermore, following Ad3 and Ad7 infection of cells containing 
a p53 plasmid and a luciferase reporter construct, though there 
was a significant increase in p53 levels, there was only a minor 
increase in reporter transcription. In addition, cells infected with 
these virus serotypes demonstrated decreased protein levels of 
p21, a p53-regulated gene, secondary to decreased levels of p21 
mRNA (18).
It remains to be seen how this variable interaction between p53 
and the different adenovirus serotypes will impact on a potential 
synergistic effect with radiotherapy. The role of p53 within the cell 
is a complex and far-reaching one, hence its moniker “the guard-
ian of the genome” (42). In particular, p53 inactivation is key in 
oncogenesis and it is mutated in approximately 50% of all cancers 
(43). Its function as a key modulator of apoptosis is, therefore, in 
balance with that of a DNA damage responder. Wild-type p53 is 
associated with enhanced chemosensitivity and radiosensitivity, 
but the exact p53-mediated cellular response to these stressors 
appears to be reliant on a range of cellular factors (44). As such, 
given the complex interactions between adenovirus infection 
and the cellular stress response, it is difficult to predict which 
p53 transcriptional pathway will ultimately be most affected by 
combination therapy.
effects of virus on DNA Repair Proteins
Effects of Virus Proteins on NHEJ
A physical interaction between an oncolytic viral protein and a 
protein heavily involved in the DNA damage response was first 
demonstrated by Boyer et al (45). Glioma cells with or without 
DNA PK were infected with either wild-type Ad5 or a mutant 
lacking E4. Concatemers formed in cells expressing DNA PK 
when these were infected by mutant virus, but not wild-type. 
Interestingly, no concatemerization was seen in cells lacking 
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DNA PK, and following plasmid transfection of 293 cells with 
plasmids expressing DNA PK and either E4orf6 or E4orf3, there 
appeared to be co-immunoprecipitation of DNA PK and these 
viral proteins.
Since this time, the major effect of multiple virus serotypes 
on NHEJ has been demonstrated to be through degradation of 
DNA ligase IV. This was initially shown in Ad5 by Baker et al., 
who demonstrated that degradation was dependent on expres-
sion of the E1b55K–E4orf6 complex and was likely mediated by 
ubiquitination and subsequent targeting by the proteasome (46).
Degradation of DNA ligase IV has also been observed post 
infection with adenovirus serotypes 3, 4, 5, 7, 9, 11, and 12 (18, 
30). Crucially, it was the only cellular protein degraded by all 
adenoviral serotypes tested by Forrester et al., suggesting that it 
plays a key role in the inhibition of the DNA damage response 
pathway by human adenoviruses (18).
Effects of Virus Proteins on HR
There is currently limited evidence on the effect of oncolytic 
viruses on HR. Tookman et  al. investigated the impact of HR 
status in ovarian cancer on adenovirus infection. Two cell lines 
were utilized, both from the same ovarian cancer patient. The 
first was obtained during a platinum-sensitive relapse, contained 
a deleterious BRCA2 mutation and was, therefore, HR defective, 
the second was obtained during a subsequent platinum-resistant 
relapse following development of a secondary BRCA2 muta-
tion which restored the open reading frame and had, therefore, 
regained HR function. Cells were infected with wild-type Ad5, 
Ad11 or Ad35, or one of two Ad5 mutants, both containing an 
E3b region deletion, one of these also containing a deletion in 
the region of E1A CR2. Interestingly, the authors found that the 
cell line with functional HR demonstrated a significant decrease 
in cell survival following infection by all three Ad5 viruses when 
compared to the cell line with defective HR. Confocal microscopy 
showed colocalization between viral replication centres (VRC) 
and BRCA2. Surprisingly, the authors also noted colocalization 
of VRC and Rad51 foci in both the presence and absence of 
BRCA2, and this was confirmed in a number of other cell lines. 
This is the first demonstration of recruitment of HR proteins to 
the adenovirus VRC. Co-immunoprecipitation was consistent 
with an interaction between Rad51 and Ad5 E2 DNA binding 
protein. Furthermore, depletion of Rad51 resulted in reduced 
cytotoxicity and viral replication following infection with the 
above-mentioned Ad5 mutants, BRCA2 depletion likewise leads 
to reduced cytotoxicity (47). These data suggest these HR proteins 
are utilized by Ad5 to improve viral replication and cytotoxicity.
ADeNOviRUS AS A RADiOSeNSiTiZeR
Adenoviruses have developed a range of interactions with cellular 
DNA damage repair proteins to allow successful viral replication. 
This has implications for the initiation of a number of DNA repair 
pathways activated in response to radiation-induced damage, in 
particular all adenoviral serotypes tested appear to target NHEJ 
repair (18). The hypothesis that oncolytic adenovirus infection 
would work synergistically with radiotherapy has been tested by 
a number of groups. The combination of CG7870 with radiation 
resulted in a synergistic increase in cell killing, both in vitro and 
in vivo in the LINPAC xenograft model, than either agent alone 
(48). Toth et al. studied 3 Ad5-based vectors and combined them 
with radiation in A549 lung cancer cells (49). Again they found 
that in vivo and in vitro tumor cell kill was increased with the 
combination approach than was seen with either agent alone. 
Similar findings have been noted with a variety of different ade-
noviral vectors in other cell types, including ovarian cancer cell 
lines (50) and glioma xenografts (51). Importantly, however, the 
effect of radiosensitization does not appear to extend to normal 
tissues. The combination of Ad5/CMV/p53 radiosensitized two 
non-small cell lung cancer cell lines (A549 and H322) in vitro and 
in xenograft models, in a synergistic fashion, but did not show 
an increased radiosensitization effect on normal lung fibroblasts 
(52). These observations provide a framework to consider the 
clinical rationale for adenovirus and radiation combinations, as 
discussed in section “Clinical Efficacy and Toxicity.”
Although radiation damage to the viral genome could render 
the particle inactive, the small size of the genome is, statistically, 
unlikely to be affected by standard X-ray photons. X-rays are 
sparsely ionizing meaning that primary ionization events are 
well separated, at least microscopically. In comparison to the 
human genome (3 ×  109  bp), the relative size of the genome 
for most therapeutically employed viruses (adenovirus is about 
3.5 × 103 bp) means the ionization events are unlikely to trouble 
the majority of particles. The ability to influence ATR and by 
extension single-strand break repair, which is a far more common 
type of cellular response to radiation, is also beneficial. Single-
strand breaks are easily repaired avoiding cell death. The arrest 
of single-strand break repair increases the likelihood of future 
catastrophic damage and apoptotic death.
RADiOTHeRAPY AND THe iMMUNe 
ReSPONSe
immune inhibition versus immune 
Stimulation
The interplay between immunostimulatory and immunoinhibi-
tory pathways in response to radiation is a complex and intricate 
one (53–55). Radiotherapy has long been thought to elicit an 
immunosuppressive effect (56, 57). A number of cell types have 
been implicated in this. Regulatory T cells have been shown to 
play an important role in the inhibition of an antitumor immune 
response following radiotherapy (58). There is also evidence 
for immunoinhibitory roles played by, and potential increased 
influx resulting from radiotherapy, of both tumor-associated 
macrophages (59, 60) and myeloid-derived suppressor cells (60, 
61). Furthermore, radiation-induced effects on dendritic cells 
have been demonstrated in  vitro to shift cytokine release away 
from activation and toward tolerization (62). Effects on differ-
ent cell types and the tumor microenvironment have recently 
been elegantly reviewed elsewhere and an in-depth discussion is 
outwith the scope of this article (53, 55, 60).
On the other hand, the body of literature presents us with 
multiple preclinical and clinical examples of ways in which the 
host antitumor immune response can actually be augmented by 
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radiotherapy (63–71). A number of mechanisms have been pro-
posed as mediating this. These include preferential radiotherapy-
mediated killing of radiosensitive suppressor T  cells (63, 64), 
increased immune cell infiltration of tumors (65), activation 
of dendritic cells (66, 67), improved antigen presentation both 
in draining lymph nodes (65) and within the tumor itself (68), 
induction/upregulation of cell surface markers that interact with 
cytotoxic T lymphocytes (69, 72), release of immunostimulatory 
molecules subsequent to radiation-induced immunogenic cell 
death (70, 71, 73), and the production of pro-inflammatory 
cytokines and chemokines (73).
We are still unable to predict which way the fine balance will 
tip in response to tumor irradiation. Interestingly, it has been 
proposed that ablative radiotherapy (typically greater than 6 Gy 
per fraction) favors a T-cell-dependent immunostimulatory anti-
tumor response when compared to more traditional fractionation 
schedules (1.8–2 Gy per fraction), which may favor an immuno-
suppressive response (66, 68, 74, 75), though Dewan et al. have 
presented data that would appear to contradict this (76). The ideal 
fractionation schedule favoring immune stimulation has yet to 
be determined and is likely to be influenced by a large number of 
host and tumor-specific variables (72). Currently, focus is shifting 
toward combining ionizing radiation with immunotherapy to tip 
the scales in favor of promoting an antitumor immune response 
(54). In particular, a number of studies are currently planned 
or ongoing focusing on combining radiation with checkpoint 
inhibitors (53).
The Abscopal effect
The abscopal effect, a phenomenon whereby ionizing radiation 
of a tumor leads to reduction of tumor growth outwith the field 
of radiation, was initially described by Mole (77). Demaria et al. 
demonstrated that it is at least partially immune mediated (78). 
Though a number of clinical cases describing the abscopal effect 
have now been documented, this phenomenon is by no means 
common (75, 79). With the advent of combination radiotherapy 
with checkpoint inhibitors, it is hoped and anticipated that cases 
demonstrating beneficial abscopal effect will become more com-
mon in the coming years.
ONCOLYTiC ADeNOviRUSeS AND THe 
iMMUNe ReSPONSe
Viruses utilize a number of mechanisms to evade the normal 
immune response. It has been proposed that the aberrant intracel-
lular pathways in cancer cells, however, make them particularly 
vulnerable to targeting by oncolytic viruses for destruction via a 
mechanism of immunogenic cell death (10). This would provide 
an alternative means by which the viruses may act synergistically 
with radiotherapy and tip the scales in favor of immunostimula-
tion. One potential mechanism to enhance this further is the 
development of armed oncolytic viruses that express immu-
nostimulatory molecules (produced locally by virus-infected 
tumor cells and released into the tumor microenvironment), 
providing further signals that can enhance an antitumor immune 
response.
Oncolytic Adenovirus Mechanisms  
of immune Stimulation
The different mechanisms of immunogenic cell death have 
recently been elegantly reviewed (80). With regard to cellular 
responses to invasion of pathogens, microorganism-associated 
molecular patterns (MAMPs)/pathogen-associated molecular 
patterns (PAMPs) interact with intra- and extracellular pattern 
recognition receptors, such as toll-like receptors and nucleotide-
binding oligomerization domain-like receptors. In response to 
viral infection, a subsequent danger response is elicited and is 
associated with formation of inflammasome complexes and 
secretion of type I interferons. Pathogens, including viruses, dem-
onstrate a range of mechanisms developed to avoid this immune 
detection and stimulation (80, 81).
In addition to PAMPs/MAMPs, virus-mediated cytotoxicity 
pathways may also be intrinsically immunogenic via damage-
associated molecular patterns. For example, Dyer et  al. have 
recently published data on the ability of Enadenotucirev (EnAd), a 
chimeric group B adenovirus currently undergoing clinical trials, 
to induce proinflammatory cell death (82). Mode of cytotoxicity 
displayed features consistent with oncosis, and infection with 
EnAd led to release of the pro-inflammatory markers heat shock 
protein 70 (HSP70) and high-mobility group box-1 (HMGB1) 
from cells. The pro-phagocytic marker calreticulin was also 
increased on tumor cells infected with EnAd. Moreover, infection 
of tumor cells lead to a significantly higher level of dendritic cell-
mediated T cell activation than wild-type Ad5. These data suggest 
that induction of immunogenic cell death may be an additional 
mechanism by which oncolytic viruses could work synergistically 
with radiotherapy.
Arming Oncolytic Adenoviruses to 
enhance immune Stimulation
A number of different mechanisms have been utilized to “arm” 
oncolytic adenovirus and enhance the immune response. For 
example, Li et  al. carried out a phase I dose escalation study 
investigating the effect of H103, a recombinant Ad2 virus over-
expressing HSP70 (83). 27 patients with advanced solid tumors 
received intratumoral treatment. Clinical benefit rate (partial 
response, minor response, or stable disease) was 48.1%, with 
11.1% experiencing partial response and, interestingly, three 
patients demonstrating transient regression of some distant non-
injected areas of metastasis, though RECIST criteria for response 
were not met. The most frequently experienced side effects were 
local injection-site reaction and fever, hematological toxicities 
were observed in five patients.
A phase I study on the intravesical use of a GM-CSF express-
ing adenovirus, CG0070, in non-muscle invasive bladder cancer 
was carried out by Burke et al. (84). Of 35 patients treated, 17 had 
complete response (CR, 48.6%), with a median CR duration of 
10.4 months. No clinically significant treatment-related toxicities 
were reported.
CGTG-602 (Ad5/3-E2F-Δ24-GMCSF) was another oncolytic 
adenovirus engineered to express GM-CSF (85). In vivo this virus 
demonstrated selective replication in tumor cells and appeared to 
induce an immune-mediated antitumor response. Intratumoral 
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administration was carried out in 13 patients with advanced 
metastatic tumors. 6 were able to be assessed with PET CT, of these 
83% demonstrated radiological disease control and PET response 
rate was 50%, including one patient who demonstrated complete 
metabolic response in a non-injected site. Tumor marker assess-
ment indicated potential benefit in 6 out of 10 patients who had 
elevated markers at baseline.
Sova et al. present data on the use of a TNF-related apoptosis-
inducing ligand (TRAIL) expressing adenovirus vector (86). This 
vector was able to induce tumor-specific apoptosis both in vitro 
and in  vivo. In a mouse model for colorectal liver metastases, 
when compared to untreated controls, intravenous administra-
tion of the vector resulted in an approximately 10-fold tumor 
burden reduction versus approximately 1.5 to 3 fold in response 
to non-TRAIL expressing vectors, and complete eradication of 
metastases in three out of five mice. There was transient elevation 
of a liver enzyme following vector infusion but no histological 
changes of normal liver tissue.
Finally, Hirvinen et  al. generated Ad5/3-D24-hTNFa, an 
oncolytic adenovirus expressing human TNFa and selective to 
retinoblastoma protein defective cells (87). Cell death caused by 
this virus in  vitro was associated with a significant increase in 
ATP release compared to control virus, and increased, but not 
significant, levels of calreticulin exposure and HMGB1 release, 
thereby displaying some features of immunogenic cell death. In 
vivo, intratumoral injection resulted in significant tumor growth 
delay and prolonged survival compared to control virus. There 
was likewise significant reduction in tumor growth compared to 
control virus in a syngeneic mouse melanoma model. Interestingly, 
the authors investigated the combination of this virus with radio-
therapy treatment in vivo and in vitro. Combination treatment 
had no impact on cell viability in vitro. In vivo, treatment with 
Ad5/3-D24-hTNFa combined with radiotherapy in a prostate 
cancer xenograft model led to a significant reduction in tumor 
growth when compared to treatment with mock or control virus 
and radiotherapy, but there was no difference between control 
virus and Ad5/3-D24-hTNFa in the immunocompetent mouse 
melanoma model, which the authors postulated may have been 
related to the inherent radioresistant nature of melanoma.
CLiNiCAL eFFiCACY AND TOXiCiTY
To date, clinical experience with virus/radiation combina-
tions has been limited to local (most commonly intratumoral) 
administration. This mode of delivery facilitates direct infection, 
ensuring correct dosing and avoiding the rapid hepatic uptake 
seen with systemic delivery (88). The downside is only tumor 
types that can be easily accessed with a needle, such as skin, head, 
and neck cancers or prostate cancers, are considered suitable for 
clinical trials. Nevertheless, the results of these studies provide us 
with useful mechanistic indicators as well as guiding assessment 
of toxicity. While the authors acknowledge that there are other 
oncolytic viruses in clinical practice, we will focus on the clinical 
experience with adenoviral agents.
A study of intraprostatic injection of an oncolytic Ad5 PSE/PBN 
E1A-AR (Ad5, adenovirus serotype 5; prostate-specific enhancer; 
PBN, rat probasin promoter; E1A, early region 1A; androgen 
receptor), combined with either low or high dose rate radiation 
therapy, showed remarkably few side effects (89). Although DNA 
damage, as assessed by γH2AX foci, viral replication and viral 
induced cell death all favored the high-dose radiation arm, the 
side effect profile was similar in both arms. This indicates that 
the therapeutic efficacy is separate from the toxicity, in contrast 
to traditional radiosensitizers where a higher dose often increases 
both efficacy and toxicity. These findings support the large body 
of preclinical data that there is little additive toxicity to that seen 
with either agent alone (90).
A phase I trial of intraprostatic injection of a replication-
competent adenovirus in combination with radical dose 
(74 Gy delivered in daily 2 Gy fractions) of intensity modu-
lated radiotherapy (IMRT) showed no significant differences 
in gastro-intestinal or genitourinary toxicity in comparison 
to the toxicity seen when administering the adenovirus as a 
single agent (91). The investigational agent had already proven 
safe and efficacious as a single agent (92). These results were 
confirmed in a follow on randomized phase II trial (93). There 
was a non-significant 42% reduction in biopsy positivity in the 
investigational arm, suggesting improved efficacy and synergy 
with radiation. Clinical outcomes at 2  years show no differ-
ence, likely reflecting the excellent prognosis of both groups. 
A phase II/III (ReCAP) open label adaptive trial of 280 men, 
randomized to combination treatment or radiation efficacy, 
with biochemical failure free survival as the primary endpoint 
(94). Other groups have shown that administering a differ-
ent type of adenovirus is safe, both concurrently and after 
radiation to the prostate (95, 96), when all cells should be at 
maximal damage and repair rates. Again, the viral compound 
was administered intratumorally.
There is also evidence from early phase clinical trials that a 
combination approach of radical dose (76 Gy delivered in 2.17 Gy 
daily fractions) with Ad5 replication defective adenoviral vector 
stimulates a systemic response (97). IMRT was commenced 
48 h after the second of three doses of the viral agent, therefore, 
patients were effectively loaded and then treated concurrently. 
Again, drug was administered intraprostatically. Both HLA DR+ 
CD8+ and CD4+ T cells were increased in the combination arm 
compared to the radiation alone arm, suggesting the potential 
development of a Th1 response.
In a mixed solid tumor cohort, an adenovirus vector under 
the control of EGF-1 promoter was combined with radiation in 
36 patients (98). 70% of subjects showed evidence of a partial 
response, with the main side effects relating to intratumoral 
administration of the agent. Using the same agent in combina-
tion with chemoradiation for squamous cell carcinomas of the 
head and neck a phase I dose escalation trial was performed (99), 
again with intratumoral administration. The main dose limiting 
toxicity (DLT) seen was thrombosis, with no increase in acute 
radiation side effect incidence or intensity, underlining the safety 
of the combination approach. Locoregional response was 83.3%. 
Preclinical studies with this agent have shown impressive ability 
to suppress regional metastatic node formation highlighting its 
ability to influence intrinsic tumor biology (100). Incrementally 
increasing doses of the same agent were also combined with 
radiation in soft tissue extremity sarcoma (101). No DLT was 
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noted and the combination was well tolerated. 91% of patients 
undergoing surgery showed a pathological CR to treatment high-
lighting significant potential synergy between both agents. The 
same adenovirus composite has been successfully combined with 
radical chemoradiotherapy (50.4 Gy delivered in 1.8 Gy daily frac-
tions concurrently with fluoropyrimidines) for locally advanced 
pancreatic cancer in a non-randomized phase I/II setting (102). 
The main DLTs were pancreatitis and cholangitis but no specific 
increases in observed acute radiotherapy or chemotherapy side 
effects, respectively, were seen. The adenovirus was administered 
intratumorally.
Combination of yet another adenovirus, designed to transfer 
p53 to malignant cells, in a radically treated non-small cell lung 
cancer population has shown impressive response data (103). 
This prospective phase II trial of 60 Gy in combination showed 
no evidence of pathologically viable tumor in 63% of patients (12 
out of 19) evaluable. The most common adverse events were virus 
related; fevers (79%), and chills (53%).
Ongoing studies in brain malignancies, such as glioblas-
toma multiforme (GBM), are also encouraging. Intratumoral 
injection at the time of surgery of an adenoviral vector 
expressing HSV thymidine kinase gene, combined with 
radical chemoradiation post operatively (104), has been tested 
prospectively. 12 of 13 patients completed therapy, at varying 
dose levels in this phase Ib trial, with no DLTs or significant 
toxicity. A phase II trial is ongoing (NCT00589875). Further 
evidence of safety in GBM patients is provided by the small 
phase I study that used a conditionally replicating HSV, G207 
(105). Following two prior safety studies with single-agent 
use, they showed, in nine patients, that intratumoral injection 
followed by 5 Gy of radiation 24 h later had no increased risk 
of toxicity. Preclinical data with G207 also points to efficacy in 
other tumor sites, such as head and neck SCC and lung cancer 
(106, 107) (see above).
Taken together, these clinical data support the safety of a com-
bination approach of radiation with a range of adenovirus con-
structs. The most commonly reported adverse events are related 
to the local administration and investigational agent itself rather 
than any increase in expected normal tissue toxicity mediated 
by excessive radiosensitization. Although clinical trials have not 
yet progressed to the point of assessing efficacy as an endpoint, 
several are in conduct. The optimum timing and sequencing 
of the two modalities has yet to be decided. So far concurrent 
delivery has been most used, appears safe and effective with no 
negative effects on viral biology. Further mechanistic work on 
sequencing is required, however. The need to access the tumor 
directly has limited the scope of clinical investigation, both in 
terms of tumor type and tumor stage. The future of oncolytic viral 
therapy really lies in newer agents with the ability to be delivered 
systemically (9, 108). This approach would not only allow the 
treatment of many more tumor sites but also, potentially, target 
micrometastatic disease such as nodal spread. The ability to suc-
cessfully access tumors remotely will offer novel opportunities 
to further understand the reciprocal biology and elucidate the 
optimal approach to combination therapy.
FUTURe DiReCTiONS
Oncolytic adenoviruses have developed several mechanisms 
to inhibit cellular DNA damage repair pathways. This creates a 
logical case for additive and potentially synergistic efficacy when 
oncolytic viruses are combined with radiotherapy, although 
the outcome may also depend on the radiotherapy protocol 
employed. Not only do these viruses promise activity as cancer-
selective radiosensitizers, the observation that some oncolytic 
adenoviruses naturally mediate an immunogenic cell death 
mechanism provides the possibility of provoking an anticancer 
immune response. Coupled with the option to express therapeu-
tic proteins selectively at the tumor site, this creates an appealing 
and potentially unique targeted immunostimulatory strategy 
that builds on the strengths of both component approaches. 
Accordingly, we anticipate the development of systemically 
administered viruses designed as cancer-targeted radiosensitiz-
ers, capable of stimulating potent anticancer immune responses 
to stimulate activity against tumor deposits both inside and 
outside the field of irradiation. Such an approach should be 
perfectly complementary to the current generation of checkpoint 
inhibitors, and it is feasible to anticipate a further increase in 
utility if all three approaches are combined in future treatment 
strategies.
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